Elisabeth R. van Wering

Author

Also Known As

E R Van Wering, E R van Wering, E. R. Van Wering, E. R. Wering, E. R. van Wering, E.R. Van Wering, E.R. van Wering, E.R.v. Wering, ER van Wering, Elisabeth R Van Wering

152

Publications

Citations

H-Index

Concepts

All Affiliations

Stichting Kinderoncologie Nederland Erasmus University Rotterdam Erasmus MC Erasmus MC - Sophia Children’s Hospital Amsterdam UMC Location Vrije Universiteit Amsterdam

About

Elisabeth R. van Wering is an author at Stichting Kinderoncologie Nederland specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	37	3K
2	Health Sciences	11	11	699
3	Education	1	1	25
4	Natural Sciences	1	1	23
5	Public Health	1	1	47

Elisabeth R. van Wering

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Jacques J. M. van Dongen, Taku Seriu, E. Renate Panzer-Grümayer, The Lancet Hematological MalignancyLymphoid NeoplasiaAcute Lymphoblastic LeukaemiaPediatric HematologyMixed-phenotype Acute Leukemia	1998	956
Fetal origins of the <i>TEL-AML1</i> fusion gene in identical twins with leukemia Anthony M. Ford, Caroline Bennett, Cathy M. Price, Proceedings of the National Academy of Sciences	1998	315
In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia Gertjan J.L. Kaspers, A. Veerman, Rob Pieters, Blood	1997	270
Protracted and Variable Latency of Acute Lymphoblastic Leukemia AfterTEL-AML1 Gene Fusion In Utero Joseph L. Wiemels, Anthony M. Ford, Elisabeth R. van Wering, Blood	1999	257
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004) A. Veerman, Willem A. Kamps, Henk van den Berg, The Lancet Oncology Hematological MalignancyProtocol All-9Lymphoid NeoplasiaOncologyHematology	2009	247
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia Pieter Van Vlierberghe, Martine van Grotel, Joëlle Tchinda, Blood	2008	222
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. A. Veerman, K. Hählen, Willem A. Kamps, Journal of Clinical Oncology	1996	208
Long-Term Results of a Randomized Trial on Extended Use of High Dose <scp>l</scp>-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia Andrea Pession, Maria Grazia Valsecchi, Giuseppe Masera, Journal of Clinical Oncology	2005	198
Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia Monique L. den Boer, D. Harms, Rob Pieters, Journal of Clinical Oncology	2003	185
Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease Tomasz Szczepański, Marja J. Willemse, Bas Brinkhof, Blood	2002	170

Page 1